Nanoparticle-Delivered Apoptosis Peptide Reduces Tumor Growth 85% When Combined with Chemotherapy | Research

The takeaway

A cell-penetrating peptide carrying an apoptosis trigger, delivered via nanoparticles, reduced tumor growth by 85% when combined with doxorubicin chemotherapy in mice.

85% tumor reduction
Combination of Smac-CPP nanoparticles with doxorubicin achieved 85% tumor growth inhibition in mice

What the researchers found

Smac-CPP nanoparticles combined with doxorubicin reduced tumor growth by 85% in vivo, with decreased Ki-67 proliferation staining and increased cleaved caspase-3 apoptosis staining in tumors.

Why it matters

Cancer cells often resist apoptosis, limiting chemotherapy effectiveness. Delivering apoptosis-triggering peptides directly into tumor cells could sensitize them to standard chemotherapy drugs.

The numbers in context

85% tumor growth reduction; 8-mer Smac + 14-mer CPP; decreased Ki-67, increased cleaved caspase-3

How the study worked

Synthesized chimeric Smac-CPP peptide (8-mer Smac + 14-mer CPP), encapsulated in PLGA nanoparticles. In vitro testing in 4T1 mammary tumor cells for uptake, viability, and caspase activation. In vivo combination therapy with doxorubicin in mouse breast cancer model.

Who was studied

4T1 breast tumor-bearing mice

What this study cannot tell us

Mouse model only with unspecified group sizes. PLGA nanoparticle manufacturing scalability not addressed. Long-term toxicity and biodistribution not reported. Only tested with one chemotherapy drug.

How to read the evidence

Preliminary — promising mouse model results with a single tumor type; no human data or long-term safety assessment.

When this study was published

Published in 2020; nanoparticle-peptide combination therapies remain an active area of preclinical cancer research.

The bigger picture

This nanoparticle-peptide approach addresses multiple challenges simultaneously: peptide stability, intracellular delivery, and chemotherapy resistance. It represents a growing trend of combining peptide therapeutics with nanotechnology for cancer treatment.

Questions still open

What is the optimal ratio of Smac-CPP-NPs to doxorubicin for maximum anti-tumor effect?
Do the nanoparticles accumulate in off-target organs, and what are the systemic side effects?
Could this approach work with other chemotherapy drugs or immunotherapies?

Common questions

What is Smac and how does it kill cancer cells?

Smac is a naturally occurring protein that promotes apoptosis (programmed cell death) by blocking proteins that protect cancer cells from dying. The Smac mimetic peptide activates this same pathway, making cancer cells vulnerable to death signals.

Why use nanoparticles to deliver the peptide?

Peptides break down quickly in the body and struggle to enter cells on their own. PLGA nanoparticles protect the peptide, deliver it to tumors through passive targeting, and release it inside cancer cells for maximum effect.

Read the original research

Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo.

International journal of pharmaceutics, 585, 119535

View on PubMed ↗Publisher’s paper ↗

Citation

Priwitaningrum, Dwi L; Jentsch, Julian; Bansal, Ruchi; Rahimian, Sima; Storm, Gert; Hennink, Wim E; Prakash, Jai. (2020). Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo.. International journal of pharmaceutics, 585, 119535. https://doi.org/10.1016/j.ijpharm.2020.119535